2024年 3月 21日
各位「Newsweek International」掲載のお知らせ
当社の子会社であるあすか製薬株式会社（東京都港区）の代表取締役社長 山口惣大が、通信社 The Worldfolio PTE. LTD.の取材を受け、米国週刊誌「Newsweek International」に会社の紹介記事が掲載されましたのでお知らせいたします。
※記事内容は添付資料をご覧ください※関連記事：「Newsweek International」掲載のお知らせ (2023 年 9 月 14 日公表)
https://www.aska-pharma-hd.co.jp/LinkClick.aspx?fileticket=WMkupSZTnMI%3d&tabid=199&mid=759

Newsweek は、世界に約 4,600 万人の読者を持つ米国の週刊誌で、世界の文化・政治・経済・社会情勢等、あらゆる分野の情報を世界に発信、展開しています。今回、特集企画「TheJapanese Firms Accelerating Medical Innovation（医療革新を加速させる日本企業）」に、日本企業の一社として紹介されました。
なお、インタビューの全文は、ニュースサイト「The WORLDFOLIO」に掲載されていますので、あわせてお知らせいたします。
「The WORLDFOLIO」ウェブサイト（英文）https://www.theworldfolio.com/interviews/aska-we-create-new-value-as-leading-womens-healthcare-company/5872/※記事の掲載は The Worldfolio PTE. LTD.の許可を得ています。
The Worldfolio PTE. LTD.：
20 年以上にわたって世界中の読者に高品質のコンテンツを提供してきたメディアエージェ
ンシーです。現在は、シンガポールを拠点に、製造、不動産、建設、ヘルスケア、デジタルトランスフォーメーションなど、幅広いトピックや最新ニュースを提供しています。
以上＜お問い合わせ先＞
あすか製薬ホールディングス株式会社 グループ経営企画部 TEL：03-5484-8366

The World's Best Hospitals

HOSPITALBOSSES ARE
BETTING ON

BIG TECH

1 5 . 0 3 . 2 0 2 4
ALBANIA €6.25
DENMARK DKR57
AUSTRALIA $11.00 EGYPT E£ 65.00
AUSTRIA €10.00
FINLAND €7.60
BAHRAIN BD4.25
FRANCE €7.50
BELGIUM €7.00
GERMANY €7.50
CHINA RM80
GIBRALTAR £6.05
CYPRUS €7.00
GREECE €7.50
CZECH REP CZK180 HOLLAND €7.00

HONG KONG HK80
LITHUANIA €8.99
HUNGARY HUF 5.990 LUXEMBOURG €7.90
IRELAND €7.00
MALTA €7.00
ISRAEL NIS35
MONTENEGRO €8.30
ITALY €7.00
MOROCCO MDH70
KUWAIT KD3.00
NEW ZEALAND $14.00
LATVIA €6.50
NIGERIA $3.40C
LEBANON LL10,000 NORWAY NKR119OMAN OR 3.250
POLAND PLN29.99
PORTUGAL €7.00
QATAR QR65
MALAYSIA RM27.90
ROMANIA LEI 42.00
SAUDI ARABIA SR35.00
S LEONE SLL30,000

SINGAPORE $11.95
SLOVAKIA €6.50
SOUTH AFRICA R55.00
SPAIN €7.00
SWEDEN SKR119SWITZERLAND
CHF10.60
UAE AED42UK £5.99
US $10.99
ZIMBABWE ZWD4.00

ASKA Pharmaceutical: Revolutionizing Women’s Healthcare
In its drive to become awomen’s healthcare pioneer,
ASKA Pharmaceutical iscommitted to innovation andglobal expansion.

“We aim to becomea total healthcarecompany and a globalentity.”
Sohta Yamaguchi,President,
ASKA Pharmaceutical

Head ofﬁce in Tokyo
ASKA Pharmaceutical is today
the leading force in Japan’s obstetrics and gynecology sector,
showcasing a relentless pursuit ofexcellence in women’s healthcarethat demonstrates its commitment beyond mere sales ﬁgures.
“We aim to become a total healthcare company and a global entity,aligning with our corporate philosophy,” says Sohta Yamaguchi,
the company’s president.
ASKA’s strategic shift to a holdings model enables the company
to offer comprehensive healthservices, from prevention to post- drugs and treatments but alsotreatment, meeting the evolving medical equipment and related
needs of a proactive populace. services, offering comprehensive
With innovative products like RE- health services for females.”And in a world where selfLUMINA (relugolix) for uterine ﬁbroids and endometriosis, and es- medication is on the rise, ASKA
sential products in the treatment Pharmaceutical sees opportuniof thyroid disease, ASKA
ties, not obstacles. “OverPharmaceutical stands
the-counter options areout by providing effecgaining popularity,
tive solutions.
and this has led to“We offer drugs
the growing healththat provide treatconsciousness ofment options for
the Japanese people
women’s health chaland the revitalization
lenges at every stage ofof the healthcare marlife,” Mr. Yamaguchiket,” he adds.
Looking forward,explains. “We aim Three core areas with ato not only provide focus on pharmaceuticals Mr. Yamaguchi en-Drugs for the treatment of thyroid
disease when launched in 1922
visions a future where ASKA
expands globally, enriching lives
beyond Japan’s borders. “By our105th anniversary in 2025, I
hope to report our successfulachievements,” he shares, hinting
at forthcoming advancements inglobal expansion and new business ventures.
In a nutshell, ASKA Pharmaceutical isn’t just about treatingailments; it’s about empowering
women, fostering health awareness, and pioneering innovations
that transcend borders. With Mr.
Yamaguchi at the helm, the company’s journey towards global leadership in women’s health seems notjust promising but inevitable.
www.aska-pharma.co.jp